Evolving Treatment for Advanced HCC - prIME Oncology
Expert Review
Expert Review

Evolving Treatment for Advanced HCC

Defining the Optimal Sequence of Therapy

Not a member of My prIME? Join now for instant access.

View a comprehensive review from leading experts in the field and downloadable slides on locoregional and systemic therapy for hepatocellular carcinoma (HCC). This activity features a discussion of current standard of care and emerging treatment options for intermediate-stage and advanced-stage HCC.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

1.0 AMA PRA Category 1 Credit™

Release Date

Release Date

Jun 29, 2018

Expiration Date

Jun 29, 2019

  • Jordi Bruix, MD, PhDUniversity of Barcelona
    Barcelona, Spain
  • Richard Finn, MDUCLA Medical Center
    Santa Monica, California, United States
  • Peter R. Galle, MD, PhDUniversity Medical Center Mainz
    Mainz, Germany
  • Introduction
  • Intermediate-Stage HCC
  • Advanced-Stage HCC
    • First-Line Therapy
    • Second-Line Therapy
    • Immunotherapy
    • AFP as a Predictive Biomarker
  • prIME Points™

This educational activity is specifically designed for medical and radiation oncologists, as well as gastrointestinal specialists who manage patients with HCC.

After successful completion of this educational activity, participants should be able to:

  • Describe locoregional treatment options for intermediate-stage HCC and identify criteria for transitioning patients from locoregional therapy to systemic therapy
  • Determine optimal systemic therapy for advanced HCC in the front-line setting and beyond
  • Assess emergent systemic therapy options for advanced-stage HCC

This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Hope on the Horizon for TNBC - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This enduring activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Bruix has disclosed that he has received consulting fees from AbbVie; Adaptimmune; ArQule, Inc.; Bayer HealthCare Pharmaceuticals, Inc.; Bristol-Myers Squibb; BTG; Eisai; Incyte; Lilly; Merck; Novartis Oncology; Roche; Sanofi, Sirtex; and Terumo Medical Corporation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Finn has disclosed that he has received consulting fees from Bayer HealthCare Pharmaceuticals, Inc.; Bristol-Myers Squibb; Eisai; Merck; Novartis Oncology; and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Galle has disclosed that he has had board membership with AstraZeneca and Roche. He has also received honoraria for promotional speaker’s bureau from Bayer HealthCare Pharmaceuticals, Inc.; Lilly; and Sirtex. He has membership on advisory committee or review panels with AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol-Myers Squibb; Eisai; Lilly; Merck; and Sirtex. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Amy Furedy, RN, OCN (clinical content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.